Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention

Human respiratory syncytial virus (hRSV) is the most important viral agent of pediatric respiratory infections worldwide. The only specific treatment available today is a humanized monoclonal antibody (Palivizumab) directed against the F glycoprotein, administered prophylactically to children at ver...

Descripción completa

Detalles Bibliográficos
Autores: Magro, Margarita, Mas-Lloret, Vicente, Chappell, Keith, Vazquez-Alcaraz, Monica, Cano, Olga, Luque, Daniel, Terrón-Orellana, Maria Carmen, Melero, Jose Antonio, Palomo-Sanz, Concepcion
Tipo de recurso: artículo
Fecha de publicación:2012
País:España
Institución:Instituto de Salud Carlos III (ISCIII)
Repositorio:Repisalud
Idioma:inglés
OAI Identifier:oai:repisalud.isciii.es:20.500.12105/17487
Acceso en línea:http://hdl.handle.net/20.500.12105/17487
Access Level:acceso abierto
Palabra clave:Amino Acid Sequence
Animals
Antibodies, Neutralizing
Antibodies, Viral
Humans
Immunization
Molecular Sequence Data
Protein Stability
Rabbits
Recombinant Proteins
Respiratory Syncytial Virus Infections
Respiratory Syncytial Virus, Human
Vaccinia virus
Viral Fusion Proteins
id ES_ea53ce3b4da0af62bb577ac971fa246d
oai_identifier_str oai:repisalud.isciii.es:20.500.12105/17487
network_acronym_str ES
network_name_str España
repository_id_str
spelling Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical interventionMagro, MargaritaMas-Lloret, VicenteChappell, KeithVazquez-Alcaraz, MonicaCano, OlgaLuque, DanielTerrón-Orellana, Maria CarmenMelero, Jose AntonioPalomo-Sanz, ConcepcionAmino Acid SequenceAnimalsAntibodies, NeutralizingAntibodies, ViralHumansImmunizationMolecular Sequence DataProtein StabilityRabbitsRecombinant ProteinsRespiratory Syncytial Virus InfectionsRespiratory Syncytial Virus, HumanVaccinia virusViral Fusion ProteinsHuman respiratory syncytial virus (hRSV) is the most important viral agent of pediatric respiratory infections worldwide. The only specific treatment available today is a humanized monoclonal antibody (Palivizumab) directed against the F glycoprotein, administered prophylactically to children at very high risk of severe hRSV infections. Palivizumab, as most anti-F antibodies so far described, recognizes an epitope that is shared by the two conformations in which hRSV_F can fold, the metastable prefusion form and the highly stable postfusion conformation. We now describe a unique class of antibodies specific for the prefusion form of this protein that account for most of the neutralizing activity of either a rabbit serum raised against a vaccinia virus recombinant expressing hRSV_F or a human Ig preparation (Respigam), which was used for prophylaxis before Palivizumab. These antibodies therefore offer unique possibilities for immune intervention against hRSV, and their production should be assessed in trials of hRSV vaccines.National Academy of SciencesMinisterio de Ciencia e Innovación (España)Instituto de Salud Carlos III20242024-02-0520122012-02-2120122012-02-21research articlehttp://purl.org/coar/resource_type/c_2df8fbb1VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articlehttp://hdl.handle.net/20.500.12105/17487reponame:Repisaludinstname:Instituto de Salud Carlos III (ISCIII)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution-NonCommercial-NoDerivatives 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:repisalud.isciii.es:20.500.12105/174872026-06-12T12:43:37Z
dc.title.none.fl_str_mv Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention
title Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention
spellingShingle Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention
Magro, Margarita
Amino Acid Sequence
Animals
Antibodies, Neutralizing
Antibodies, Viral
Humans
Immunization
Molecular Sequence Data
Protein Stability
Rabbits
Recombinant Proteins
Respiratory Syncytial Virus Infections
Respiratory Syncytial Virus, Human
Vaccinia virus
Viral Fusion Proteins
title_short Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention
title_full Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention
title_fullStr Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention
title_full_unstemmed Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention
title_sort Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention
dc.creator.none.fl_str_mv Magro, Margarita
Mas-Lloret, Vicente
Chappell, Keith
Vazquez-Alcaraz, Monica
Cano, Olga
Luque, Daniel
Terrón-Orellana, Maria Carmen
Melero, Jose Antonio
Palomo-Sanz, Concepcion
author Magro, Margarita
author_facet Magro, Margarita
Mas-Lloret, Vicente
Chappell, Keith
Vazquez-Alcaraz, Monica
Cano, Olga
Luque, Daniel
Terrón-Orellana, Maria Carmen
Melero, Jose Antonio
Palomo-Sanz, Concepcion
author_role author
author2 Mas-Lloret, Vicente
Chappell, Keith
Vazquez-Alcaraz, Monica
Cano, Olga
Luque, Daniel
Terrón-Orellana, Maria Carmen
Melero, Jose Antonio
Palomo-Sanz, Concepcion
author2_role author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Ministerio de Ciencia e Innovación (España)
Instituto de Salud Carlos III
dc.subject.none.fl_str_mv Amino Acid Sequence
Animals
Antibodies, Neutralizing
Antibodies, Viral
Humans
Immunization
Molecular Sequence Data
Protein Stability
Rabbits
Recombinant Proteins
Respiratory Syncytial Virus Infections
Respiratory Syncytial Virus, Human
Vaccinia virus
Viral Fusion Proteins
topic Amino Acid Sequence
Animals
Antibodies, Neutralizing
Antibodies, Viral
Humans
Immunization
Molecular Sequence Data
Protein Stability
Rabbits
Recombinant Proteins
Respiratory Syncytial Virus Infections
Respiratory Syncytial Virus, Human
Vaccinia virus
Viral Fusion Proteins
description Human respiratory syncytial virus (hRSV) is the most important viral agent of pediatric respiratory infections worldwide. The only specific treatment available today is a humanized monoclonal antibody (Palivizumab) directed against the F glycoprotein, administered prophylactically to children at very high risk of severe hRSV infections. Palivizumab, as most anti-F antibodies so far described, recognizes an epitope that is shared by the two conformations in which hRSV_F can fold, the metastable prefusion form and the highly stable postfusion conformation. We now describe a unique class of antibodies specific for the prefusion form of this protein that account for most of the neutralizing activity of either a rabbit serum raised against a vaccinia virus recombinant expressing hRSV_F or a human Ig preparation (Respigam), which was used for prophylaxis before Palivizumab. These antibodies therefore offer unique possibilities for immune intervention against hRSV, and their production should be assessed in trials of hRSV vaccines.
publishDate 2012
dc.date.none.fl_str_mv 2012
2012-02-21
2012
2012-02-21
2024
2024-02-05
dc.type.none.fl_str_mv research article
http://purl.org/coar/resource_type/c_2df8fbb1
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv http://hdl.handle.net/20.500.12105/17487
url http://hdl.handle.net/20.500.12105/17487
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution-NonCommercial-NoDerivatives 4.0 Internacional
http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution-NonCommercial-NoDerivatives 4.0 Internacional
http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv National Academy of Sciences
publisher.none.fl_str_mv National Academy of Sciences
dc.source.none.fl_str_mv reponame:Repisalud
instname:Instituto de Salud Carlos III (ISCIII)
instname_str Instituto de Salud Carlos III (ISCIII)
reponame_str Repisalud
collection Repisalud
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869423130487816192
score 15,81155

Similares en LA Referencia